A Bispecific Antibody To Synergise Checkpoint Blockers In Oncology
Funder
National Health and Medical Research Council
Funding Amount
$636,492.00
Summary
Cancer hides from the immune system in its earliest stages by evading immune surveillance and a cell type named myeloid derived suppressor cell (MDSC) has been identified as the main accomplice in this evasion. Currently, there is no drugs able to specifically target those cells. Here, we will develop a new drug that will prevent their recruitment to the tumors. We believe that when use in synergy with recent immunotherapies, it will dramatically improve survival in cancer patients.
Cancer is now the number one killer of Australians and there is an unmet medical need to develop new therapies that are safe and maximize anti-cancer efficacy. Cancer immunotherapy now represents a new fourth pillar in cancer treatment to complement surgery, radiotherapy and chemo-/targeted therapies. This application aims to develop new therapeutic approaches to broaden the effectiveness of cancer immunotherapy and potentially allow the treatment of a broader range of cancers and patients.
Development Of A New Surgical-guidance Tool For Intra-operative Tumour Margin Assessment In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$557,982.00
Summary
One third of breast cancer patients undergoing breast conserving surgery have insufficient tissue removed, resulting in an increased risk of recurrence. We have developed a high resolution optical imaging probe with the potential to detect small areas of cancer. It could be used to help guide the surgeon to remove all cancerous tissue from the patient. This grant will allow us to develop the probe to a stage that it can be used during surgery, and perform the world’s first clinical scans.
Development Of Novel Gene Therapy Vectors For Thalassaemia
Funder
National Health and Medical Research Council
Funding Amount
$287,307.00
Summary
Thalassaemia, is a common inherited disorder affecting haemoglobin synthesis. Synthesis of ?/?-globin chain is balanced during normal red blood cell production. Any disruption in the ratio of ?/?-globin chain results in anaemia. In this study, we will explore gene therapy strategies to restore balanced ?:? globin expression and ultimately improve the severely anaemic phenotype in ?-thalassaemia patients.
Development Of Therapeutic Copper Delivery Agents For Menkes Disease
Funder
National Health and Medical Research Council
Funding Amount
$651,467.00
Summary
Menkes disease does not currently have an effective treatment. The disease is caused by genetic defects that reduce copper transport into the brain and cause mental retardation and death. We have developed drugs that deliver copper into the brain and should cure Menkes disease. We aim to demonstrate that our drugs are effective in mice that have the same genetic defect as patients. Successful results will allow us to begin treating Menkes disease patients to determine if we can cure the disease.